These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29331155)

  • 1. Performance of a Novel Antipseudomonal Antibiotic Consumption Metric Among Academic Medical Centers in the United States.
    Markley JD; Pakyz AL; Sabo RT; Bearman G; Hohmann SF; Stevens MP
    Infect Control Hosp Epidemiol; 2018 Feb; 39(2):229-232. PubMed ID: 29331155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in a novel antipseudomonal antimicrobial consumption metric across hospital inpatient units at a Veterans Affairs hospital: A retrospective cohort study.
    Vissichelli NC; Bailey P; Sabo RT; Tassone D; Vaughan L; Stevens MP; Markley JD
    Am J Infect Control; 2019 Oct; 47(10):1263-1264. PubMed ID: 31153713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Antipseudomonal Agent Use Based on the 2006 to 2015 Sales Data in Japan.
    Ebisui A; Inose R; Kusama Y; Koizumi R; Kawabe A; Ishii S; Goto R; Ishikane M; Yagi T; Ohmagari N; Muraki Y
    Biol Pharm Bull; 2021; 44(6):816-821. PubMed ID: 34078813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study.
    Khadem T; Stevens V; Holt K; Hoffmann C; Dumyati G; Brown J
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):146-150. PubMed ID: 28780998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
    McDougall DA; Morton AP; Playford EG
    J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia.
    Djordjevic Z; Folic M; Ruzic Zecevic D; Ilic G; Jankovic S
    J Infect Dev Ctries; 2013 Sep; 7(9):686-90. PubMed ID: 24042106
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
    Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
    J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
    Eagye KJ; Nicolau DP
    Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units.
    Zou Y; Lian J; Di Y; You H; Yao H; Liu J; Dong Y
    Int J Clin Pharm; 2018 Feb; 40(1):175-182. PubMed ID: 29134489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
    Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
    Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
    Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapies for pseudomonas aeruginosa.
    Giamarellou H; Kanellakopoulou K
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation.
    Elgarten CW; Arnold SD; Li Y; Huang YV; Riches ML; Gerber JS; Aplenc R; Saber W; Fisher BT
    Infect Control Hosp Epidemiol; 2018 Jul; 39(7):797-805. PubMed ID: 29734957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
    Kamata K; Suzuki H; Kanemoto K; Tokuda Y; Shiotani S; Hirose Y; Suzuki M; Ishikawa H
    J Infect Chemother; 2015 Aug; 21(8):596-603. PubMed ID: 26070781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
    Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
    Fujimura S; Nakano Y; Sato T; Shirahata K; Watanabe A
    J Infect Chemother; 2007 Jun; 13(3):147-50. PubMed ID: 17593500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.
    Slama TG
    Crit Care; 2008; 12(5):233. PubMed ID: 18983709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
    Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.